162 related articles for article (PubMed ID: 32196701)
1. Dual in vitro invasion/migration suppressing and tamoxifen response modulating effects of a recombinant anti-ALCAM scFv on breast cancer cells.
Darvishi B; Salehi M; Boroumandieh S; Majidzadeh-A K; Jalili N; Moradi-Kalbolandi S; Farahmand L
Cell Biochem Funct; 2020 Jul; 38(5):651-659. PubMed ID: 32196701
[TBL] [Abstract][Full Text] [Related]
2. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
3. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
4. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis.
Davies S; Jiang WG
Anticancer Res; 2010 Apr; 30(4):1163-8. PubMed ID: 20530423
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells.
Fernández MM; Ferragut F; Cárdenas Delgado VM; Bracalente C; Bravo AI; Cagnoni AJ; Nuñez M; Morosi LG; Quinta HR; Espelt MV; Troncoso MF; Wolfenstein-Todel C; Mariño KV; Malchiodi EL; Rabinovich GA; Elola MT
Biochim Biophys Acta; 2016 Oct; 1860(10):2255-68. PubMed ID: 27130882
[TBL] [Abstract][Full Text] [Related]
6. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
7. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.
Ferragut F; Cagnoni AJ; Colombo LL; Sánchez Terrero C; Wolfenstein-Todel C; Troncoso MF; Vanzulli SI; Rabinovich GA; Mariño KV; Elola MT
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1338-1352. PubMed ID: 30905597
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA expression profiling and the role of ALCAM modulating tumor growth and metastasis in benzo[a]pyrene-transformed 16HBE cells.
Li L; Chen J; Wang Y; Zhou C; Ma X; Fu J; Yao B; Zhao P
Toxicology; 2020 Sep; 442():152539. PubMed ID: 32681969
[TBL] [Abstract][Full Text] [Related]
9. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
10. ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions.
Willrodt AH; Salabarria AC; Schineis P; Ignatova D; Hunter MC; Vranova M; Golding-Ochsenbein AM; Sigmund E; Romagna A; Strassberger V; Fabbi M; Ferrini S; Cursiefen C; Neri D; Guenova E; Bock F; Halin C
Front Immunol; 2019; 10():759. PubMed ID: 31031759
[TBL] [Abstract][Full Text] [Related]
11. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion.
Achiha T; Kijima N; Kodama Y; Kagawa N; Kinoshita M; Fujimoto Y; Nonaka M; Fukai J; Inoue A; Nishida N; Yamanaka T; Harada A; Mori K; Tsuyuguchi N; Uda T; Ishibashi K; Tomogane Y; Sakamoto D; Shofuda T; Yoshioka E; Kanematsu D; Mano M; Luu B; Taylor MD; Kanemura Y; Kishima H
PLoS One; 2020; 15(12):e0243272. PubMed ID: 33270750
[TBL] [Abstract][Full Text] [Related]
12. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.
Hansen AG; Arnold SA; Jiang M; Palmer TD; Ketova T; Merkel A; Pickup M; Samaras S; Shyr Y; Moses HL; Hayward SW; Sterling JA; Zijlstra A
Cancer Res; 2014 Mar; 74(5):1404-15. PubMed ID: 24385212
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Association with Promoter Methylation of the ALCAM Gene in Breast Cancer.
Jeong YJ; Oh HK; Park SH; Bong JG
Molecules; 2018 Jan; 23(1):. PubMed ID: 29315254
[TBL] [Abstract][Full Text] [Related]
14. Sonic Hedgehog Signalling Activation Contributes to ALCAM Over-Expression and Poor Clinical Outcome in Patients with Oral Squamous Cell Carcinoma.
Chen G; Yan M; Li RR; Chen WT
Chin J Dent Res; 2018; 21(1):31-40. PubMed ID: 29507910
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
16. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
[TBL] [Abstract][Full Text] [Related]
17. MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway.
Jiang Z; Zhang J; Chen F; Sun Y
Thorac Cancer; 2020 Feb; 11(2):415-425. PubMed ID: 31883226
[TBL] [Abstract][Full Text] [Related]
18. Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer.
Tan F; Mosunjac M; Adams AL; Adade B; Taye O; Hu Y; Rizzo M; Ofori-Acquah SF
BMC Cancer; 2014 Sep; 14():715. PubMed ID: 25255861
[TBL] [Abstract][Full Text] [Related]
19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
20. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer.
Tantivejkul K; Vucenik I; Eiseman J; Shamsuddin AM
Breast Cancer Res Treat; 2003 Jun; 79(3):301-12. PubMed ID: 12846414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
